Press Release 瑞石生物医药有限公司

Press Release

R&D investment exceeds RMB 100 million! A approved clinical trial of the new drug intended to be used in the treatment of alopecia areata by Reistone Biopharma

Hengrui Medicine (600276) announced in the evening that Reistone Biopharma Company Limited, a subsidiary of the company, recently received the Notice of Clinical Trial approved and issued by NMPA.

2020-02-21 Learn more
Chasing Dreams in Medicine Valley | Min Wang Irwin of Reistone Biopharma: China's power to explore the global autoimmune diseases

Reistone, led by Min Wang Irwin, has been a new force to Zhangjiang Biopharma Base in recent years.

2019-08-17 Learn more
Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn's Disease

SHANGHAI, June 14, 2019 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone) announced today dosing of the first patient in their Phase II global clinical trials (RSJ10101 and RSJ10201) of SHR0302 in patients with Ulcerative Colitis and Crohn's d

2019-06-28 Learn more